

Institutional Ethics Committee
Institute of Human Behaviour & Allied Sciences, Delhi

Version 2; 31 May, 2022

Annexure 6. Application Form for Clinical Trials

Title of study:

Principal Investigator (Name, Designation and Affiliation)

1. Type of clinical trial Regulatory trial ☐ Academic trial ☐

CTRI registration number:

NABH accreditation number

EC registration number:

2. If regulatory trial, provide status of CDSCO permission letter
- Approved and letter attached ☐
- Applied, under process ☐
- Not applied (State reason)

- 3.
- | | | | |
|---|--------------------------|---|--------------------------|
| Phase - I | <input type="checkbox"/> | Phase II | <input type="checkbox"/> |
| Phase III | <input type="checkbox"/> | Phase IV or Post Marketing Surveillance | <input type="checkbox"/> |
| Investigational medicinal products | <input type="checkbox"/> | Investigational New drug | <input type="checkbox"/> |
| Medical devices | <input type="checkbox"/> | New innovative procedure | <input type="checkbox"/> |
| Drug/device combination | <input type="checkbox"/> | Bioavailability/Bioequivalence studies | <input type="checkbox"/> |
| Non-drug intervention | <input type="checkbox"/> | Repurposing an existing intervention | <input type="checkbox"/> |
| Indian system of medicine (AYUSH) | <input type="checkbox"/> | Stem cells | <input type="checkbox"/> |
| Phytopharmaceutical drug | <input type="checkbox"/> | Approved drug for any new indication or new route of administration | <input type="checkbox"/> |
| Others (specify) <input type="checkbox"/> | | | |

Tick all categories that apply to your trial

Institutional Ethics Committee
Institute of Human Behaviour & Allied Sciences, Delhi

Version 2; 31 May, 2022

4. Trial design of the study (May choose more than one)

I.

Randomized	<input type="checkbox"/>	Factorial	<input type="checkbox"/>
Nonrandomized	<input type="checkbox"/>	Stratified	<input type="checkbox"/>
Parallel	<input type="checkbox"/>	Adaptive	<input type="checkbox"/>
Cross-over	<input type="checkbox"/>	Comparison trial	<input type="checkbox"/>
Cluster	<input type="checkbox"/>	Superiority trial	<input type="checkbox"/>
Matched pair	<input type="checkbox"/>	Non-inferiority trial	<input type="checkbox"/>
Others (specify)	<input type="checkbox"/>	Equivalence trial	<input type="checkbox"/>

II. If there is randomization, how will the participants be allocated to the control and study group(s)?

III. Describe the method of allocation concealment (blinding / masking), if applicable

5. List the primary / secondary outcomes of the trial.

6. Is there a Contract Research Organization (CRO) /Site Management Organization (SMO) / Any Other Agency such as public relation/Human resource? Yes ☐ No ☐

If yes, Name and Contact details:

State how the CRO/SMO/agency will be involved in the conduct of the trial (tick all that apply)

Project management	<input type="checkbox"/>	Clinical and medical monitoring	<input type="checkbox"/>
Regulatory affairs	<input type="checkbox"/>	Data management	<input type="checkbox"/>
Statistical support	<input type="checkbox"/>	Medical writing	<input type="checkbox"/>
Site management	<input type="checkbox"/>	Audits, quality control, quality assurance	<input type="checkbox"/>
Finance management	<input type="checkbox"/>	Recruitment and training	<input type="checkbox"/>
Administrative support	<input type="checkbox"/>	Others (specify)	<input type="checkbox"/>

Please provide the following details about the intervention being used in the protocol

Institutional Ethics Committee
Institute of Human Behaviour & Allied Sciences, Delhi

Version 2; 31 May, 2022

I. Drug/s, device/s and/or biologics; If yes, provide regulatory approval details

Yes ☐ No ☐ NA ☐

II. Already approved drugs or a combination of two or more drugs with new indications / change in dosage form / route of administration. If yes, provide details

Yes ☐ No ☐ NA ☐

III. Provide contact details of who prepared and /or is manufacturing the drug(s), device(s) and biologics

IV. Provide details of patent of the drug/s, device/s and biologics.

8. Describe in brief any preparatory work or site preparedness for the protocol?

Yes ☐ No ☐ NA ☐

If yes, (100 words)

9. Is there an initial screening/ use of existing database for participant selection?

Yes ☐ No ☐ NA ☐

If Yes, provide details *(In order to select participants for your protocol does the protocol require you to screen an initial population or refer to an existing database before shortlisting participants. If yes, provide details on the same)*

10. Are there any anticipated incidence, frequency and duration of adverse events related to the intervention? If yes, provide details of arrangements made to address them.

Yes ☐ No ☐ NA ☐

Does the study use a placebo?

If yes, justify the use of the placebo and risks entailed to participants.

Yes ☐ No ☐ NA ☐

Will current standard of care be provided to the control arm in the study?

Yes ☐ No ☐ NA ☐

If no, please justify.

Are there any plans to withdraw standard therapy during the study? If yes, please justify.

Yes ☐ No ☐ NA ☐

Institutional Ethics Committee
Institute of Human Behaviour & Allied Sciences, Delhi

Version 2; 31 May, 2022

Are there any rules to stop the protocol in case of any adverse events? If yes, please specify.

Yes ☐ No ☐ NA ☐

Does the study have a Data and Safety Monitoring Plan? If no, please justify.

Yes ☐ No ☐

Participant Information Sheet (PIS) and Informed Consent Form (ICF)

English ☐ Local language ☐ Other (*Specify*) ☐

(Certified that local version (s) is/are a true translation of the English version and can be easily understood by the participants)

List the languages in which translations were done

Justify if translation not done

17. Involvement/consultation of statistician in the study design Yes ☐ No ☐ NA ☐

18. Is there any insurance coverage of the trial? If yes, provide details. Yes ☐ No ☐

19. Is the PI registered with Medical Council of India (MCI) or the State Medical Council registration? Please provide details.

Yes ☐ No ☐

20. Is the PI trained in GCP in last 3 years? If yes, please enclose certificate

Yes ☐ No ☐

Signature of PI:

[Click here to enter a date.](#)